breast cancer metastasis to liver survival rate

Release time ：Dec-20,2024

The prognosis for patients with breast cancer that has metastasized to the liver is generally poor. The occurrence of liver metastasis signifies that the disease has advanced to a later stage, with cancer cells having disseminated from the primary site to the liver via the bloodstream or lymphatic system. Statistically, the five-year survival rate for these patients is estimated to be between 20% and 30%.

Several factors significantly influence prognosis. The type and grade of the tumor are critical; for instance, patients with triple-negative breast cancer and liver metastasis tend to have a worse prognosis compared to those with hormone receptor-positive breast cancer. Additionally, the number and size of metastatic lesions are important; patients with a solitary and smaller metastatic lesion generally have a more favorable prognosis. Other factors, such as the patient's age, overall health, and the presence of metastases to other organs, also impact survival rates.

Early detection and treatment are crucial for improving survival rates in patients with breast cancer liver metastasis. Regular health check-ups and imaging studies are advised for breast cancer patients to promptly identify potential liver metastases. Upon confirmation of breast cancer liver metastasis, patients should immediately begin standardized treatment under the guidance of a specialized physician. This treatment may include a combination of surgery, chemotherapy, radiation therapy, and targeted therapies. Maintaining a positive attitude and actively engaging in treatment with healthcare providers can enhance the quality of life and potentially extend survival.